Phio Pharmaceuticals Corp. Common Stock (PHIO) Stock Price

PHIOStock

$1.13−42.93%52W

Market Cap$13.13M

P/E—

PEG Ratio—

Div yield—

Beta0.85

PHIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.30%

Price vs S&P 500 (4W)8.17%

VGM Score41.41

Book Value / Share (Quarterly)$1.42

P/TBV (Annual)0.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.92

Price vs S&P 500 (YTD)-5.20%

Net Profit Margin (TTM)-3935.71%

EPS (TTM)$-1.49

10-Day Avg Trading Volume0.22M

EPS Excl Extra (TTM)$-1.49

EPS (Annual)$-9.05

ROI (Annual)-151.39%

Net Profit Margin (5Y Avg)-38214.76%

Cash / Share (Quarterly)$1.47

ROA (Last FY)-124.61%

EBITD / Share (TTM)$-1.47

ROE (5Y Avg)-105.54%

Operating Margin (TTM)-3957.14%

Cash Flow / Share (Annual)$-0.69

P/B Ratio0.77x

P/B Ratio (Quarterly)0.86x

Net Income / Employee (Annual)$-1,191,700

EV / Revenue (TTM)-31.62x

Net Interest Coverage (TTM)-1328.00x

ROA (TTM)-70.87%

EPS Incl Extra (Annual)$-9.05

Current Ratio (Annual)16.03x

Quick Ratio (Quarterly)17.93x

3-Month Avg Trading Volume0.47M

52-Week Price Return-42.93%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.13

P/S Ratio (Annual)630.24x

Asset Turnover (Annual)0.00x

52-Week High$4.19

Operating Margin (5Y Avg)-39948.09%

EPS Excl Extra (Annual)$-9.05

CapEx CAGR (5Y)-9.71%

Tangible BV CAGR (5Y)42.68%

26-Week Price Return4.63%

Quick Ratio (Annual)15.69x

13-Week Price Return-0.88%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.32x

Enterprise Value$-4.43M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-42.30%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-44550.00%

Cash / Share (Annual)$1.81

3-Month Return Std Dev62.35%

Net Income / Employee (TTM)$-1,822,000

ROE (Last FY)-151.39%

EPS Basic Excl Extra (Annual)$-9.05

Receivables Turnover (TTM)0.33x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.49

ROI (TTM)-77.34%

P/S Ratio (TTM)90.03x

Pretax Margin (5Y Avg)-39834.76%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.52

Price vs S&P 500 (52W)-61.49%

Year-to-Date Return7.62%

5-Day Price Return-3.42%

EPS Normalized (Annual)$-9.05

ROA (5Y Avg)-88.07%

Net Profit Margin (Annual)-44550.00%

Month-to-Date Return10.24%

Cash Flow / Share (TTM)$-7.19

EBITD / Share (Annual)$-9.35

Operating Margin (Annual)-44950.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-105.31%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.49

P/TBV (Quarterly)0.32x

P/B Ratio (Annual)0.56x

Pretax Margin (TTM)-3935.71%

Book Value / Share (Annual)$1.73

Price vs S&P 500 (13W)-2.83%

Beta0.85x

Revenue / Share (TTM)$0.00

ROE (TTM)-77.34%

52-Week Low$0.81

mGradeC

vgmGradeC

PHIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.36	-$0.36	+0.00%(+$0.00)
Q1 2026	May 7, 2026	-$0.23	-$0.34	-44.68%(-$0.11)
Q4 2025	Mar 5, 2026	-$0.47	-$0.15	+68.09%(+$0.32)
Q3 2025	Nov 13, 2025	-$0.44	-$0.44	+0.00%(+$0.00)
Q2 2025	Aug 14, 2025	-$0.36	-$0.45	-25.00%(-$0.09)

PHIO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
PHIOPhio Pharmaceuticals Corp. Common Stock	—	—	C	$1.13
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Phio Pharmaceuticals Corp. Common Stock

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL RNA gene silencing technology to enhance immune cells' ability to kill tumor cells. The platform precisely targets proteins that suppress anti-cancer immunity without requiring specialized drug delivery systems. The company's pipeline includes candidates PH-762 and PH-894, with all operations based in the United States.